Skip to main content
Fig. 4 | BMC Pharmacology and Toxicology

Fig. 4

From: Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation

Fig. 4

Rosiglitazone activated the phosphorylation of Akt and PKCβ. a HUVECs were treated with rosiglitazone (10 μM) with or without PI3K inhibitors LY294002 (1 μM), Akt inhibitor (3.5 μM), or PKCβ inhibitor (1.5 μM) simultaneously. Cells were stained with anti-phospho-Akt antibody. b and c Immunoblot analysis for the phosphorylation of Akt and PKCβ (n = 4)

Back to article page